Brief: Cantargia Intensifies Development Of Nadunolimab In Pancreatic Cancer With Controlled Phase IIb Clinical Trial
15/05/2023 14:19
May 15 (Reuters) - Cantargia AB CANTA.ST :
* INTENSIFIES DEVELOPMENT OF NADUNOLIMAB IN PANCREATIC
CANCER WITH
CONTROLLED PHASE IIB CLINICAL TRIAL FOLLOWING STRONG PHASE IIA
RESULTS
* REGULATORY SUBMISSION IS PLANNED FOR H2 2023 WITH TOP LINE
DATA
PLANNED FOR 2025
Source text for Eikon: ID:nMFN67F6Z
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML